Mark D. Booth
2013
In 2013, Mark D. Booth earned a total compensation of $1.3M as Chief Commercial Officer outgoing at Orexigen Therapeutics, a 5% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $162,800 |
|---|---|
| Option Awards | $814,188 |
| Salary | $296,000 |
| Other | $8,326 |
| Total | $1,281,314 |
Booth received $814.2K in option awards, accounting for 64% of the total pay in 2013.
Booth also received $162.8K in non-equity incentive plan, $296K in salary and $8.3K in other compensation.
Rankings
In 2013, Mark D. Booth's compensation ranked 5,573rd out of 12,286 executives tracked by ExecPay. In other words, Booth earned more than 54.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,573 out of 12,286 | 55th |
Division Manufacturing | 1,945 out of 4,612 | 58th |
Major group Chemicals And Allied Products | 567 out of 1,462 | 61st |
Industry group Drugs | 404 out of 1,156 | 65th |
Industry Pharmaceutical Preparations | 324 out of 890 | 64th |
Source: SEC filing on April 22, 2015.
Booth's colleagues
We found four more compensation records of executives who worked with Mark D. Booth at Orexigen Therapeutics in 2013.
2013
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2013
Joseph Hagan
Orexigen Therapeutics
Former Chief Business and Financial Officer
2013
Preston Klassen
Orexigen Therapeutics
Executive Vice President, Global Product Development
2013
Heather Turner
Orexigen Therapeutics